Synteract

Synteract was founded in 1995 by individuals including Ellen Morgan, who also served as its CEO. The company established itself as a full-service contract research organization (CRO), providing essential services for Phase I-IV clinical trials. Its business focused on supporting emerging to mid-sized biopharmaceutical clients, carving out a niche by offering expertise in complex therapeutic areas like oncology, neuroscience, and rare diseases. The company grew by managing thousands of clinical trials across dozens of countries, demonstrating its global reach. A key part of its strategy involved targeted acquisitions to enhance its specialized capabilities, such as purchasing Cu-Tech in 2018 to create a dedicated dermatology development center. This focus on specialization made Synteract a valuable partner for smaller biotech firms needing comprehensive support to navigate the drug development process. A significant milestone in Synteract's journey occurred in late 2020 when it was acquired by Syneos Health. The acquisition was a strategic move for Syneos Health to strengthen its position in the fast-growing small to mid-sized biopharma market. Following the acquisition, Synteract continued to operate under its own brand as a business unit within Syneos Health, maintaining its focus on its specialized client base while leveraging the larger company's scale and resources.